Skyscape Web Viewer : The Maudsley Prescribing Guidelines in Psychiatry : Main Index

View All
Leukopenia, psychotropic agent effects
Levetiracetam, for tardive dyskinesia
Levomepromazine Quick reference for licensed maximum doses Relative adverse effects - a rough guide
Lewy body dementia Dementia Parkinson's disease
Libido
Licensed maximum doses of antipsychotics, according to US Food and Drug Administration labelling, where available
Linaclotide, for constipation treatment
Linear dose reductions of olanzapine cause increasingly large reductions in D2 dopaminergic receptor blockade.
Linear reductions of dose cause increasingly large reductions in effect on GABA-A receptor occupancy.
Linear reductions of dose cause increasingly large reductions in effect on receptor targets, probably associated with more withdrawal effects.
Lipoproteins in blood, psychotropic agent effects
Liraglutide, for antipsychotic-induced weight gain
Lisdexamfetamine attention deficit hyperactivity disorder in adults borderline personality disorder bulimia nervosa/binge eating disorder
Lithium: clinically relevant drug interactions
Lithium: prescribing and monitoring
Lithium plasma levels
Lithium use with
Lithium
liver function tests (LFTs) interpretation monitoring to access drug effects
Lofepidrine, in overdose
Lofexidine, clozapine-induced hypersalivation
Lone atrial fibrillation
long-acting injectable (LAI)
Long-acting injectable antipsychotic medications - doses and frequencies
Long-acting oral antipsychotics improving adherence preventing sudden cessation restarting after period of non-compliance
Loop diuretics, lithium interaction
Loperamide, safety in older patients/dementia
Lorazepam Acutely disturbed or violent behaviour Catatonia catatonia treatment concentration in normal dosing and UK legal limit rapid tranquillisation of children and adolescents use in patients with hepatic impairment
low-density lipoprotein (LDL)
low-dose aspirin co-prescribed with SSRIs, GI bleeding risk